Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03681951
Title First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

pancreatic ductal adenocarcinoma

Advanced Solid Tumor

triple-receptor negative breast cancer

lung non-small cell carcinoma

melanoma

Therapies

GSK3145095

GSK3145095 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
GSK Investigational Site Indianapolis Indiana 46202 United States Details
GSK Investigational Site New York New York 10016 United States Details
GSK Investigational Site New York New York 10032 United States Details
GSK Investigational Site New York New York 10065 United States Details
GSK Investigational Site Philadelphia Pennsylvania 19111 United States Details
GSK Investigational Site Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field